US 12,290,524 B1
Methods and compositions for testosterone production
Saviz Cameron Sepah, Santa Monica, CA (US)
Assigned to Maximus Health, Inc., Santa Monica, CA (US)
Filed by Maximus Health, Inc., Santa Monica, CA (US)
Filed on May 15, 2024, as Appl. No. 18/664,867.
Claims priority of provisional application 63/615,679, filed on Dec. 28, 2023.
Int. Cl. A61K 31/568 (2006.01); A61K 9/00 (2006.01); A61K 31/138 (2006.01); A61K 31/573 (2006.01); A61K 47/12 (2006.01); A61K 47/38 (2006.01); A61K 47/44 (2017.01); A61P 5/26 (2006.01)
CPC A61K 31/568 (2013.01) [A61K 9/0053 (2013.01); A61K 9/006 (2013.01); A61K 31/138 (2013.01); A61K 31/573 (2013.01); A61K 47/12 (2013.01); A61K 47/38 (2013.01); A61K 47/44 (2013.01); A61P 5/26 (2018.01)] 12 Claims
OG exemplary drawing
 
1. A method of increasing testosterone levels in a subject in need thereof, comprising administering to the subject:
i) a first composition in a form suitable for sublingual administration comprising:
a) about 1 mg to about 50 mg of enclomiphene citrate;
b) cellulose;
c) a non-nutritive sweetener;
d) a flavoring agent; and
e) magnesium stearate; and
ii) at least one second composition in a form suitable for oral administration and lymphatic absorption comprising:
a) about 100 mg to about 800 mg of testosterone base or testosterone ester;
b) safflower oil;
c) cellulose; and
d) magnesium stearate.